Trial Outcomes & Findings for Dose-Finding Pediatric and Adult Trial With Sugammadex (Org 25969, MK-8616, SCH 900616) (19.4.306) (MK-8616-034) (P05961) (NCT NCT00421148)

Last Updated: 2019-01-28

Results Overview

Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds \& assessing twitch response at the adductor pollicis muscle. T1 \& T4 refer to the magnitudes (heights) of the first \& fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from neuromuscular blockade (NMB). In this study, twitch responses were recorded until the T4/T1 Ratio reached ≥0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.9 indicates a faster recovery from NMB.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

94 participants

Primary outcome timeframe

From start of sugammadex or palcebo administration to recovery of T4/T1 ratio to 0.9 (ranging from ~0.5 minutes to ~30 minutes from sugammadex or placebo administration)

Results posted on

2019-01-28

Participant Flow

Recruited participants were stratified between Infants (28 days-23 months of age), Children (2-11 years of age), Adolescents (12-17 years of age) and Adults (18-65 years of age). For Participant Flow, participants are included in the treatment group to which they were randomized.

One adolescent participant was inadvertently randomized to Children: Sugammadex 4 mg/kg, but was included in Adolescents: Sugammadex 4 mg/kg for safety analyses. One participant was randomized to Adolescents: Sugammadex 0.5 mg/kg, but received sugammadex 5.0 mg/kg \& was included in the Adolescents: Sugammadex 4 mg/kg for safety analyses.

Participant milestones

Participant milestones
Measure	Infants: Placebo Infant participants received an intravenous (IV) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Infants: Sugammadex 0.5 mg/kg Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Infants: Sugammadex 1 mg/kg Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Infants: Sugammadex 2 mg/kg Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Infants: Sugammadex 4 mg/kg Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Children: Placebo Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Children: Sugammadex 0.5 mg/kg Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Children: Sugammadex 1 mg/kg Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered	Children: Sugammadex 2 mg/kg Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Children: Sugammadex 4 mg/kg Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Adolescents: Placebo Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Adolescents: Sugammadex 0.5 mg/kg Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Adolescents: Sugammadex 1 mg/kg Adolescents participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Adolescents: Sugammadex 2 mg/kg Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Adolescents: Sugammadex 4 mg/kg Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Adults: Placebo Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Adults: Sugammadex 0.5 mg/kg Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Adults: Sugammadex 1 mg/kg Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Adults: Sugammadex 2 mg/kg Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Adults: Sugammadex 4 mg/kg Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.
Overall Study STARTED	2	2	2	1	1	5	6	5	5	5	6	6	6	6	6	6	6	6	6	6
Overall Study Treated	2	2	2	1	1	4	6	5	5	5	6	6	6	6	6	6	6	5	5	6
Overall Study COMPLETED	2	2	2	1	1	4	6	5	5	5	6	6	6	6	6	6	6	4	5	6
Overall Study NOT COMPLETED	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2	1	0

Reasons for withdrawal

Reasons for withdrawal
Measure	Children: Placebo Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Adults: Sugammadex 1 mg/kg Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Adults: Sugammadex 2 mg/kg Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.
Overall Study Lost to Follow-up	0	1	0
Overall Study Withdrawal by Subject	0	1	0
Overall Study Protocol Violation	1	0	1

Baseline Characteristics

Dose-Finding Pediatric and Adult Trial With Sugammadex (Org 25969, MK-8616, SCH 900616) (19.4.306) (MK-8616-034) (P05961)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Infants: Placebo n=2 Participants Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Infants: Sugammadex 0.5 mg/kg n=2 Participants Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Infants: Sugammadex 1 mg/kg n=2 Participants Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Infants: Sugammadex 2 mg/kg n=1 Participants Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Children: Placebo n=4 Participants Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Children: Sugammadex 0.5 mg/kg n=6 Participants Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Children: Sugammadex 1 mg/kg n=5 Participants Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered	Children: Sugammadex 2 mg/kg n=5 Participants Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Children: Sugammadex 4 mg/kg n=4 Participants Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Adolescents: Placebo n=6 Participants Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Adolescents: Sugammadex 0.5 mg/kg n=5 Participants Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Adolescents: Sugammadex 1 mg/kg n=6 Participants Adolescents participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Adolescents: Sugammadex 2 mg/kg n=6 Participants Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Adolescents: Sugammadex 4 mg/kg n=8 Participants Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Adults: Placebo n=6 Participants Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Adults: Sugammadex 0.5 mg/kg n=6 Participants Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Adults: Sugammadex 1 mg/kg n=5 Participants Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Adults: Sugammadex 2 mg/kg n=5 Participants Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Adults: Sugammadex 4 mg/kg n=6 Participants Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Infants: Sugammadex 4 mg/kg n=1 Participants Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Total n=91 Participants Total of all reporting groups
Age, Continuous	1 Years STANDARD_DEVIATION 0 • n=5 Participants	1 Years STANDARD_DEVIATION 0 • n=7 Participants	1 Years STANDARD_DEVIATION 0 • n=5 Participants	0 Years STANDARD_DEVIATION NA • n=4 Participants	9 Years STANDARD_DEVIATION 1 • n=21 Participants	9 Years STANDARD_DEVIATION 3 • n=10 Participants	8 Years STANDARD_DEVIATION 2 • n=115 Participants	9 Years STANDARD_DEVIATION 2 • n=24 Participants	6 Years STANDARD_DEVIATION 3 • n=42 Participants	15 Years STANDARD_DEVIATION 2 • n=42 Participants	14 Years STANDARD_DEVIATION 1 • n=42 Participants	15 Years STANDARD_DEVIATION 2 • n=42 Participants	14 Years STANDARD_DEVIATION 0 • n=36 Participants	14 Years STANDARD_DEVIATION 2 • n=36 Participants	49 Years STANDARD_DEVIATION 12 • n=24 Participants	41 Years STANDARD_DEVIATION 17 • n=135 Participants	37 Years STANDARD_DEVIATION 8 • n=136 Participants	38 Years STANDARD_DEVIATION 10 • n=44 Participants	38 Years STANDARD_DEVIATION 14 • n=667 Participants	1 Years STANDARD_DEVIATION NA • n=7 Participants	19.8 Years STANDARD_DEVIATION 16.40 • n=6 Participants
Sex: Female, Male Female	2 Participants n=5 Participants	2 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	5 Participants n=10 Participants	3 Participants n=115 Participants	3 Participants n=24 Participants	2 Participants n=42 Participants	3 Participants n=42 Participants	0 Participants n=42 Participants	3 Participants n=42 Participants	3 Participants n=36 Participants	4 Participants n=36 Participants	0 Participants n=24 Participants	2 Participants n=135 Participants	2 Participants n=136 Participants	1 Participants n=44 Participants	2 Participants n=667 Participants	0 Participants n=7 Participants	38 Participants n=6 Participants
Sex: Female, Male Male	0 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants	1 Participants n=4 Participants	3 Participants n=21 Participants	1 Participants n=10 Participants	2 Participants n=115 Participants	2 Participants n=24 Participants	2 Participants n=42 Participants	3 Participants n=42 Participants	5 Participants n=42 Participants	3 Participants n=42 Participants	3 Participants n=36 Participants	4 Participants n=36 Participants	6 Participants n=24 Participants	4 Participants n=135 Participants	3 Participants n=136 Participants	4 Participants n=44 Participants	4 Participants n=667 Participants	1 Participants n=7 Participants	53 Participants n=6 Participants

PRIMARY outcome

Timeframe: From start of sugammadex or palcebo administration to recovery of T4/T1 ratio to 0.9 (ranging from ~0.5 minutes to ~30 minutes from sugammadex or placebo administration)

Population: The Per Protocol (PP) population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo) \& had ≥1 post-baseline efficacy measurement for this outcome measure \& had no protocol violations. For efficacy, participants with incorrect randomization were included under the planned dose group.

Outcome measures

Outcome measures
Measure	Infants: Placebo n=2 Participants Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Infants: Sugammadex 0.5 mg/kg n=2 Participants Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Infants: Sugammadex 1 mg/kg n=2 Participants Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Infants: Sugammadex 2 mg/kg n=1 Participants Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Children: Placebo n=4 Participants Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Children: Sugammadex 0.5 mg/kg n=5 Participants Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Children: Sugammadex 1 mg/kg n=5 Participants Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered	Children: Sugammadex 2 mg/kg n=4 Participants Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Children: Sugammadex 4 mg/kg n=4 Participants Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Adolescents: Placebo n=5 Participants Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Adolescents: Sugammadex 0.5 mg/kg n=5 Participants Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Adolescents: Sugammadex 1 mg/kg n=6 Participants Adolescents participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Adolescents: Sugammadex 2 mg/kg n=6 Participants Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Adolescents: Sugammadex 4 mg/kg n=6 Participants Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Adults: Placebo n=6 Participants Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Adults: Sugammadex 0.5 mg/kg n=5 Participants Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Adults: Sugammadex 1 mg/kg n=5 Participants Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Adults: Sugammadex 2 mg/kg n=5 Participants Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Adults: Sugammadex 4 mg/kg n=5 Participants Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Infants: Sugammadex 4 mg/kg n=1 Participants Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.
Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.9	20.98 Minutes Standard Deviation 11.30	3.72 Minutes Standard Deviation 0.63	2.42 Minutes Standard Deviation 0.70	0.58 Minutes Standard Deviation NA NA=Not calculated on 1 participant	19.57 Minutes Standard Deviation 10.97	5.22 Minutes Standard Deviation 3.50	3.95 Minutes Standard Deviation 3.23	1.20 Minutes Standard Deviation 0.35	1.57 Minutes Standard Deviation 1.90	22.77 Minutes Standard Deviation 13.10	11.97 Minutes Standard Deviation 17.65	1.77 Minutes Standard Deviation 0.37	1.87 Minutes Standard Deviation 1.70	1.08 Minutes Standard Deviation 0.25	29.48 Minutes Standard Deviation 8.43	3.77 Minutes Standard Deviation 1.12	1.62 Minutes Standard Deviation 0.30	1.27 Minutes Standard Deviation 0.27	1.37 Minutes Standard Deviation 0.38	0.67 Minutes Standard Deviation NA NA=Not calculated on 1 participant

SECONDARY outcome

Timeframe: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.7 (ranging from ~0.4 minutes to ~20 minutes from sugammadex or placebo administration)

Population: The PP population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo) \& had ≥1 post-baseline efficacy measurement for this outcome measure \& had no protocol violations. For efficacy, participants with incorrect randomization were included under the planned dose group.

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds \& assessing twitch response at the adductor pollicis muscle. T1 \& T4 refer to the magnitudes (heights) of the first \& fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.7 indicates a faster recovery from NMB.

Outcome measures

Outcome measures
Measure	Infants: Placebo n=2 Participants Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Infants: Sugammadex 0.5 mg/kg n=2 Participants Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Infants: Sugammadex 1 mg/kg n=2 Participants Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Infants: Sugammadex 2 mg/kg n=1 Participants Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Children: Placebo n=4 Participants Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Children: Sugammadex 0.5 mg/kg n=5 Participants Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Children: Sugammadex 1 mg/kg n=5 Participants Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered	Children: Sugammadex 2 mg/kg n=4 Participants Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Children: Sugammadex 4 mg/kg n=4 Participants Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Adolescents: Placebo n=6 Participants Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Adolescents: Sugammadex 0.5 mg/kg n=5 Participants Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Adolescents: Sugammadex 1 mg/kg n=6 Participants Adolescents participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Adolescents: Sugammadex 2 mg/kg n=6 Participants Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Adolescents: Sugammadex 4 mg/kg n=6 Participants Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Adults: Placebo n=6 Participants Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Adults: Sugammadex 0.5 mg/kg n=5 Participants Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Adults: Sugammadex 1 mg/kg n=5 Participants Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Adults: Sugammadex 2 mg/kg n=5 Participants Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Adults: Sugammadex 4 mg/kg n=5 Participants Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Infants: Sugammadex 4 mg/kg n=1 Participants Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.
Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.7	14.85 Minutes Standard Deviation 8.65	2.47 Minutes Standard Deviation 0.07	1.78 Minutes Standard Deviation 0.18	0.58 Minutes Standard Deviation NA NA=Not calculated on 1 participant	12.32 Minutes Standard Deviation 7.00	2.62 Minutes Standard Deviation 0.93	1.45 Minutes Standard Deviation 0.38	0.75 Minutes Standard Deviation 0.12	0.57 Minutes Standard Deviation 0.13	18.62 Minutes Standard Deviation 9.72	2.77 Minutes Standard Deviation 1.27	1.07 Minutes Standard Deviation 0.12	0.95 Minutes Standard Deviation 0.30	0.83 Minutes Standard Deviation 0.20	19.65 Minutes Standard Deviation 5.38	1.62 Minutes Standard Deviation 0.25	1.27 Minutes Standard Deviation 0.35	0.87 Minutes Standard Deviation 0.23	1.12 Minutes Standard Deviation 0.38	0.42 Minutes Standard Deviation NA NA=Not calculated on 1 participant

SECONDARY outcome

Timeframe: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.8 (ranging from ~0.5 minutes to ~25 minutes from sugammadex or placebo administration)

Outcome measures

Outcome measures
Measure	Infants: Placebo n=2 Participants Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Infants: Sugammadex 0.5 mg/kg n=2 Participants Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Infants: Sugammadex 1 mg/kg n=2 Participants Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Infants: Sugammadex 2 mg/kg n=1 Participants Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Children: Placebo n=4 Participants Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Children: Sugammadex 0.5 mg/kg n=5 Participants Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Children: Sugammadex 1 mg/kg n=5 Participants Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered	Children: Sugammadex 2 mg/kg n=4 Participants Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Children: Sugammadex 4 mg/kg n=4 Participants Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Adolescents: Placebo n=6 Participants Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Adolescents: Sugammadex 0.5 mg/kg n=5 Participants Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Adolescents: Sugammadex 1 mg/kg n=6 Participants Adolescents participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Adolescents: Sugammadex 2 mg/kg n=6 Participants Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Adolescents: Sugammadex 4 mg/kg n=6 Participants Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Adults: Placebo n=6 Participants Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Adults: Sugammadex 0.5 mg/kg n=5 Participants Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Adults: Sugammadex 1 mg/kg n=5 Participants Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Adults: Sugammadex 2 mg/kg n=5 Participants Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Adults: Sugammadex 4 mg/kg n=5 Participants Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Infants: Sugammadex 4 mg/kg n=1 Participants Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.
Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.8	17.85 Minutes Standard Deviation 10.42	2.97 Minutes Standard Deviation 0.07	2.03 Minutes Standard Deviation 0.17	0.58 Minutes Standard Deviation NA NA=Not calculated on 1 participant	14.20 Minutes Standard Deviation 8.32	3.42 Minutes Standard Deviation 1.40	1.85 Minutes Standard Deviation 0.70	0.95 Minutes Standard Deviation 0.23	0.75 Minutes Standard Deviation 0.45	21.92 Minutes Standard Deviation 12.52	4.92 Minutes Standard Deviation 4.08	1.35 Minutes Standard Deviation 0.17	0.98 Minutes Standard Deviation 0.38	0.87 Minutes Standard Deviation 0.18	24.77 Minutes Standard Deviation 9.33	2.22 Minutes Standard Deviation 0.60	1.37 Minutes Standard Deviation 0.35	1.07 Minutes Standard Deviation 0.23	1.27 Minutes Standard Deviation 0.30	0.67 Minutes Standard Deviation NA NA=Not calculated on 1 participant

Deaths: 0 deaths

Adults: Sugammadex 2 mg/kg

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

Adults: Sugammadex 4 mg/kg

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Infants: Placebo n=2 participants at risk Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Infants: Sugammadex .0.5 mg/kg n=2 participants at risk Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Infants: Sugammadex 1 mg/kg n=2 participants at risk Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Infants: Sugammadex 2 mg/kg n=1 participants at risk Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Infants: Sugammadex 4 mg/kg n=1 participants at risk Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Children: Placebo n=4 participants at risk Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered	Children: Sugammadex 0.5 mg/kg n=6 participants at risk Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Children: Sugammadex 1 mg/kg n=5 participants at risk Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Children: Sugammadex 2 mg/kg n=5 participants at risk Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Children: Sugammadex 4 mg/kg n=4 participants at risk Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Adolescents: Placebo n=6 participants at risk Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered	Adolescents: Sugammadex 0.5 mg/kg n=5 participants at risk Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Adolescents: Sugammadex 1 mg/kg n=6 participants at risk Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Adolescents: Sugammadex 2 mg/kg n=6 participants at risk Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Adolescents: Sugammadex 4 mg/kg n=8 participants at risk Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Adults: Placebo n=6 participants at risk Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered	Adults: Sugammadex 0.5 mg/kg n=6 participants at risk Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Adults: Sugammadex 1 mg/kg n=5 participants at risk Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Adults: Sugammadex 2 mg/kg n=5 participants at risk Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Adults: Sugammadex 4 mg/kg n=6 participants at risk Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.
Infections and infestations Gastroenteritis viral	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	50.0% 1/2 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	25.0% 1/4 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.

Other adverse events

Other adverse events
Measure	Infants: Placebo n=2 participants at risk Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered.	Infants: Sugammadex .0.5 mg/kg n=2 participants at risk Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Infants: Sugammadex 1 mg/kg n=2 participants at risk Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Infants: Sugammadex 2 mg/kg n=1 participants at risk Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Infants: Sugammadex 4 mg/kg n=1 participants at risk Infant participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Children: Placebo n=4 participants at risk Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered	Children: Sugammadex 0.5 mg/kg n=6 participants at risk Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Children: Sugammadex 1 mg/kg n=5 participants at risk Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Children: Sugammadex 2 mg/kg n=5 participants at risk Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Children: Sugammadex 4 mg/kg n=4 participants at risk Child participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Adolescents: Placebo n=6 participants at risk Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered	Adolescents: Sugammadex 0.5 mg/kg n=5 participants at risk Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Adolescents: Sugammadex 1 mg/kg n=6 participants at risk Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Adolescents: Sugammadex 2 mg/kg n=6 participants at risk Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Adolescents: Sugammadex 4 mg/kg n=8 participants at risk Adolescent participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.	Adults: Placebo n=6 participants at risk Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of placebo (sodium chloride 0.9% solution) was administered	Adults: Sugammadex 0.5 mg/kg n=6 participants at risk Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex was administered.	Adults: Sugammadex 1 mg/kg n=5 participants at risk Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex was administered.	Adults: Sugammadex 2 mg/kg n=5 participants at risk Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex was administered.	Adults: Sugammadex 4 mg/kg n=6 participants at risk Adult participants received an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex was administered.
Reproductive system and breast disorders Scrotal oedema	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	25.0% 1/4 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Gastrointestinal disorders Constipation	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	20.0% 1/5 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Gastrointestinal disorders Diarrhoea	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	100.0% 1/1 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Gastrointestinal disorders Nausea	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	20.0% 1/5 • Number of events 2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	50.0% 4/8 • Number of events 5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Gastrointestinal disorders Vomiting	50.0% 1/2 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	50.0% 1/2 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	100.0% 1/1 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	50.0% 2/4 • Number of events 2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	50.0% 3/6 • Number of events 4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	40.0% 2/5 • Number of events 6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	20.0% 1/5 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	75.0% 3/4 • Number of events 3 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	50.0% 3/6 • Number of events 4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	50.0% 3/6 • Number of events 4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	25.0% 2/8 • Number of events 3 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
General disorders Hyperthermia	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
General disorders Pain	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	33.3% 2/6 • Number of events 2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
General disorders Pyrexia	50.0% 1/2 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Infections and infestations Nasopharyngitis	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	100.0% 1/1 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Infections and infestations Pharyngitis	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	100.0% 1/1 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	12.5% 1/8 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Infections and infestations Rhinitis	50.0% 1/2 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Injury, poisoning and procedural complications Anaemia postoperative	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	50.0% 2/4 • Number of events 2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Injury, poisoning and procedural complications Ankle fracture	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	20.0% 1/5 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Injury, poisoning and procedural complications Haematuria traumatic	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	20.0% 1/5 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Injury, poisoning and procedural complications Post procedural complication	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Injury, poisoning and procedural complications Postoperative fever	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	20.0% 1/5 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Injury, poisoning and procedural complications Procedural complication	50.0% 1/2 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Injury, poisoning and procedural complications Procedural hypotension	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Injury, poisoning and procedural complications Procedural pain	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	25.0% 1/4 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	33.3% 2/6 • Number of events 3 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	20.0% 1/5 • Number of events 2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	40.0% 2/5 • Number of events 2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	25.0% 1/4 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	50.0% 3/6 • Number of events 3 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	20.0% 1/5 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	50.0% 3/6 • Number of events 3 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	50.0% 3/6 • Number of events 3 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	50.0% 4/8 • Number of events 5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	40.0% 2/5 • Number of events 2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	20.0% 1/5 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Injury, poisoning and procedural complications Wrist fracture	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	20.0% 1/5 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Investigations Oxygen saturation decreased	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	20.0% 1/5 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	50.0% 1/2 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	20.0% 1/5 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Nervous system disorders Dizziness	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	12.5% 1/8 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Nervous system disorders Headache	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Nervous system disorders Hyperkinesia	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	20.0% 1/5 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Nervous system disorders Hypoaesthesia	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Nervous system disorders Paraesthesia	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Psychiatric disorders Anxiety	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	20.0% 1/5 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Psychiatric disorders Excitability	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Psychiatric disorders Sleep disorder	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	40.0% 2/5 • Number of events 2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Renal and urinary disorders Dysuria	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	25.0% 1/4 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Renal and urinary disorders Urinary retention	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	25.0% 1/4 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	25.0% 1/4 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Skin and subcutaneous tissue disorders Pruritus generalised	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	20.0% 1/5 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	20.0% 1/5 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.
Vascular disorders Hot flush	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/2 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/4 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	16.7% 1/6 • Number of events 1 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/8 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/5 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.	0.00% 0/6 • Through postoperative Day 7 (Up to 8 days) The APT population consisted of all randomized participants who received a dose of study treatment (sugammadex or placebo). With respect to the APT population, participants with incorrect randomization were included under the actual dose group they received.

Additional Information

Senior Vice President, Global Clinical Development

Merck Sharp & Dohme Corp.

Phone: 1-800-672-6372

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Organon recognizes the right of the investigator(s) to publish, but all publications must be based on data validated by Organon. Any such scientific paper, presentation, or other communication concerning the clinical trial described in this protocol will first be submitted to Organon, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.
Publication restrictions are in place

Restriction type: OTHER